biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Should a comparison be made between Bioasis and Denali?

<< Previous

Bullboard Posts

Next >>

Comment by Sniper007on Dec 22, 2020 8:12pm

256 Views

Post# 32166565

RE:RE:RE:Should a comparison be made between Bioasis and Denali?

Some good points and posts profetoffacts... nice to have you on the board.

I thought this was an interesting comment you made that certainly has some merit:

BTI may now be on a more validated path than xB3-001 and cancer. This may make comparisons to Denali much more marketable in 2021 and beyond with data, etc.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages